News

Sep 14, 2018
HD Integrated Report 2018
Sep 12, 2018
HD We updated Analyst Coverage information.
Aug 8, 2018
HD We updated our ESG data pages.
Aug 7, 2018
HD Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2019
Aug 6, 2018
HD Notice Concerning Completion of Payment in Full for Disposal of Treasury Stock for Restricted Stock Compensation
July 17, 2018
HD Notice concerning the Disposal of Treasury Stock for Restricted Stock Compensation
July 17, 2018
HD Notice Concerning Amendment to Consolidated Financial Results for the Fiscal Year Ended March 31, 2018
July 11, 2018
HD IR Day 〜 Q&A Session about 2020 Medium – Term Business Plan 〜 [June 19, 2018]
July 2, 2018
HD Notice Concerning Completion of Acquisition of shares of KM Biologics that was transferred Kaketsuken's main business in the form of contribution in kind and Members of the Board of the new company
June 29, 2018
PHARMA Announcement of an Approval for OPALMON TABLET 5 µg, an Oral Prostaglandin E1 Analogue, in Thailand
June 12, 2018
HD Approach and Policy Concerning Lowering of Trading Unit
June 5, 2018
HD Notice of the 9th Ordinary General Meeting of Shareholders
May 28, 2018
HD Notice Concerning Amendment to the Representative Directors of Meiji Group Companies
May 24, 2018
HD Notice Concerning Amendment to Supplementary Explanatory Data of Consolidated Financial Results for the Fiscal Year Ended March 31, 2018
May 18, 2018
HD 【Presentation】Financial Results for the Fiscal Year Ended March 31, 2018
May 11, 2018
HD Notice concerning surplus dividends
May 11, 2018
HD Notice concerning the Representative Directors of Meiji Group Companies [May 28, 2018 update]
May 11, 2018
HD Consolidated Financial Results for the Fiscal Year Ended March 31, 2018（July 17, 2018）
Mar 27, 2018
PHARMA MEIJI AND ARYSTA ENTER INTO LICENSING AGREEMENT CONCERNING NEW INSECTICIDE FLUPYRIMIN IN INDIA
Mar 13, 2018
HD Notice Concerning Signing of the Definitive Agreement with Kaketsuken to acquire shares of a company that will be transferred Kaketsuken's main business in the form of contribution in kind and to make the company a consolidated subsidiary
Feb 7, 2018
HD Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2018
Feb 1, 2018
PHARMA PRIMARY ENDPOINT MET IN PHASE II / III CLINICAL STUDY OF INVESTIGATIONAL PARKINSON'S DISEASE TREATMENT SAFINAMIDE IN JAPAN